More than 500,000 people in the United States are taking drugs for epilepsy, a growing number of them being prescribed by doctors who also prescribe opiates, according to the latest figures from the Centers for Disease Control and Prevention.
The rise in prescriptions for epilepsy drugs was driven by the opioid crisis, which has caused millions of Americans to miss work and become homeless.
The CDC released new data Thursday, showing the number of prescriptions for opiates rose by 10% in 2017 to 6.9 million people.
That’s up from 4.2 million in 2016.
The data, obtained by CNN from the U.S. Department of Health and Human Services, is a snapshot of the current state of prescribing for opiate-based drugs, as well as how many people were prescribed the medications.
The increase in opiate prescriptions has coincided with the emergence of a new class of opiate medication called clonazepam, which is an anesthetic that was first approved in 2015 and has been used for decades to treat people with epilepsy.
The CDC said that this class of drugs was being prescribed to an increasing number of people, and that the rise in prescription for clonafloxacin (CLON) in 2017 was likely due to a change in the federal guidelines for prescribing opioids.
The new guidelines have been updated every five years since 2002, and new patients are now required to have a prescription for CLON for at least three months before receiving it.
The number of CLON prescriptions rose to 669,814 in 2017, up from 611,903 in 2016, according the CDC.
Clonafluxon (CLOF) prescriptions increased to 447,742, up 14% from 447 in 2016 and up 24% from 397 in 2015.
Clonafluoxon (CLEF) prescriptions rose by 18% to 578,788, while CLOF prescriptions increased by 18.5% to 1.3 million, up 10% from 1.2 in 2016 — more than twice as many as CLOF.CLOF is also the first drug to be approved for treating patients with chronic pain, which was announced by the U of S last year.
That drug was also approved by the FDA in December 2017.
“It’s a very interesting situation where the market is in flux right now,” said Dr. Paul S. Vinciguerra, chief medical officer of the University of Michigan Health System, which runs a treatment center that specializes in treating patients who are using opiates.
“The number one thing that I would do as a physician, if I were in that position, would be to be careful about prescribing opiates,” he said.
Clinicians are also beginning to ask patients about other potential treatments that might be helpful.
For example, some patients may be prescribed another drug, and they may want to test for an anti-inflammatory, a pain reliever or even a heart-rate monitor.
In a report released earlier this year, the CDC said more than 3.5 million Americans were prescribed at least one type of opioid medication in 2017.
That represented a 25% increase from the year before, and it was the most since the CDC started tracking prescriptions in 2011.
While the opioid epidemic has created a new set of opioid drugs that are more potent, they also contain more side effects, according Toensing.
He says that can create a lot of confusion.
“People have been prescribing opiate medications to treat some of their health conditions that are not the primary ones they’re seeing,” he told CNN.
“They’re seeing more of these other medications and the side effects are more prevalent.”
I would say it’s a little scary, because I would hope that the public would be aware of those potential side effects and take care to minimize them.
“Clonazapine is one of the newer opiate drugs that have been approved for treatment of severe pain.
It is a newer class of opioid that was approved in 2016 in the U: “clonazolam” and “cloverleaf.”
Cloverleaf was the first of the new opioids to be released, and was approved for use by the Food and Drug Administration in 2017 and 2018.
It is not the first time that a new opiate drug has come to market.
In 2017, the FDA approved the first opiate of the brand name Xanax for use in adults over the age of 21.
Xanax is the brand of the antidepressant zoloft.
The FDA did not give a reason for the delay in approving Xanax.
According to data from the National Institutes of Health, more than a quarter of all prescriptions for the new opioid medication were written by doctors with specialties in psychiatry, and another 25% were written for pain management.
The other 15% were for anxiety, addiction treatment and sleep disorders.
The vast majority of prescriptions were for benzodiazepines, which include oxycodone, morphine and fentanyl.